Brief: Enanta Pharmaceuticals Announces Positive Topline Results For EDP-323
26/09/2024 11:06
Sept 26 (Reuters) - Enanta Pharmaceuticals Inc ENTA.O :
* ENANTA PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE RESULTS
FOR
EDP-323 IN A PHASE 2A HUMAN CHALLENGE STUDY OF HEALTHY ADULTS
INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV)
* ENANTA PHARMACEUTICALS INC - EDP-323 ACHIEVES SIGNIFICANT
REDUCTIONS IN VIRAL LOAD AND SYMPTOMS
* ENANTA PHARMACEUTICALS INC: FAVORABLE SAFETY AND
TOLERABILITY
OBSERVED
* ENANTA PHARMACEUTICALS INC: TREATMENT WITH ONCE-DAILY
EDP-323
MET PRIMARY AND SECONDARY ENDPOINTS
Source text for Eikon: ID:nBw6WWZ5Za
Further company coverage: ENTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enanta Pharmaceuticals
See all newsEnanta Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Enanta Pharmaceuticals Q3 revenue misses estimates, hurt by lower royalties
Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs
Enanta Pharmaceuticals Q1 revenue beats estimates